BET bromodomain inhibitors in leukemia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Experimental Hematology

• Publication date

  2015-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.exphem.2015.06.004PMID 26163798
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.

  2015cited by this paper
• Histone core modifications regulating nucleosome structure and dynamics

  2014cited by this paper
• Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells

  2014cited by this paper
• BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD

  2014cited by this paper
• Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

  2014cited by this paper
• The Bromodomain Inhibitor CPI203 Demonstrates Preclinical Synergistic Activity with Bortezomib in Drug Resistant Myeloma

  2014cited by this paper
• A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

  2014cited by this paper
• Enhancer biology and enhanceropathies

  2014cited by this paper
• An atlas of active enhancers across human cell types and tissues

  2014cited by this paper
• BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones

  2014cited by this paper
• BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma

  2014cited by this paper
• Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition

  2014cited by this paper
• c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.

  2014cited by this paper
• Master transcription factors and mediator establish super-enhancers at key cell identity genes.

  2013cited by this paper
• Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia

  2013influential reference
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• Control of transcriptional elongation.

  2013cited by this paper
• Selective inhibition of tumor oncogenes by disruption of super-enhancers.

  2013influential reference
• BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia

  2013cited by this paper
• Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription

  2013cited by this paper
• BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1

  2013cited by this paper
• Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting.

  2013cited by this paper
• Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation

  2013cited by this paper
• eRNAs promote transcription by establishing chromatin accessibility at defined genomic loci.

  2013cited by this paper
• Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release.

  2013cited by this paper
• REPRINTS AND REFLECTIONS

  2012cited by this paper
• Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)

  2012cited by this paper
• RNA polymerase II elongation control.

  2012cited by this paper
• Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.

  2012cited by this paper
• Cancer epigenetics: from mechanism to therapy.

  2012cited by this paper
• Targeting epigenetic readers in cancer.

  2012cited by this paper
• Bromodomain-containing Protein 4 (BRD4) Regulates RNA Polymerase II Serine 2 Phosphorylation in Human CD4+ T Cells*

  2012cited by this paper
• The bromodomain interaction module

  2012cited by this paper
• BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

  2012cited by this paper
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

  2011cited by this paper
• The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3

  2011cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• Two-pronged Binding with Bromodomain-containing Protein 4 Liberates Positive Transcription Elongation Factor b from Inactive Ribonucleoprotein Complexes*

  2011cited by this paper
• Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia.

  2010cited by this paper
• Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis.

  2010cited by this paper
• Suppression of inflammation by a synthetic histone mimic

  2010cited by this paper
• The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.

  2010cited by this paper
• A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.

  2010cited by this paper
• Double bromodomain‐containing gene Brd2 is essential for embryonic development in mouse

  2009cited by this paper
• The role of human bromodomains in chromatin biology and gene transcription.

  2009cited by this paper
• Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia

  2009cited by this paper
• The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription.

  2008cited by this paper
• Brd4 Coactivates Transcriptional Activation of NF-κB via Specific Binding to Acetylated RelA

  2008cited by this paper
• The Double Bromodomain-containing Chromatin Adaptor Brd4 and Transcriptional Regulation*

  2007influential reference
• Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Interacts with Bromodomain Protein Brd4 on Host Mitotic Chromosomes

  2006cited by this paper
• Reading signals on the nucleosome with a new nomenclature for modified histones

  2005cited by this paper
• The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.

  2005cited by this paper
• Growth and Early Postimplantation Defects in Mice Deficient for the Bromodomain-Containing Protein Brd4

  2002cited by this paper
• A Mammalian Bromodomain Protein, Brd4, Interacts with Replication Factor C and Inhibits Progression to S Phase

  2002cited by this paper
• Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.

  2001cited by this paper
• Structure and ligand of a histone acetyltransferase bromodomain

  1999cited by this paper
• NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.

  1998cited by this paper
• Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways.

  1998cited by this paper

• Mechanistic role of GNE‐987 targeting BRD4‐HCP5 axis in pediatric T‐cell acute lymphoblastic leukemia

  2026cites this paper
• Dual / bifunctional targeting of bromodomain and extra-terminal (BET) proteins: Expanding the paradigm of epigenetic drug discovery.

  2025cites this paper
• BRD4 inhibitor reduces exhaustion and blocks terminal differentiation in CAR-T cells by modulating BATF and EGR1

  2024cites this paper
• OTX015 PROTACs: Emerging Novel Therapeutic Agents in Cancer Treatment

  2024cites this paper
• A Combination of CPI-0610 and SAHA Induces Apoptosis through STAT3 and p38 Signalling Pathways in Diffuse Large B-cell Lymphoma Cells.

  2023cites this paper
• NMR Molecular Replacement Provides New Insights into Binding Modes to Bromodomains of BRD4 and TRIM24

  2022cites this paper
• BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

  2022cites this paper
• Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies

  2022cites this paper
• Histone Modifications and Their Targeting in Lymphoid Malignancies

  2021cites this paper
• Current advances on the development of BET inhibitors: insights from computational methods.

  2020cites this paper
• Covalent-fragment screening of BRD4 identifies a ligandable site orthogonal to the acetyl-lysine binding sites.

  2020cites this paper
• Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors’ Therapeutic Sensitivity in Acute Myeloid Leukemia

  2020cites this paper
• An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism

  2020cites this paper
• Pinning Down the Transcription: A Role for Peptidyl-Prolyl cis-trans Isomerase Pin1 in Gene Expression

  2020cites this paper
• Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications

  2019cites this paper
• Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

  2019cites this paper
• Epigenetic modifications of histones in cancer

  2019cites this paper
• Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia

  2019cites this paper
• Covalent-Fragment Screening of Brd4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites

  2019cites this paper
• 急性髓系白血病中组蛋白甲基化修饰调控异常及相关靶向治疗研究进展

  2018cites this paper
• PLX51107, a promising novel bromodomain and extra-terminal inhibitor in chronic lymphoid leukemia treatment

  2018cites this paper
• The Role of EZH2 in the Induction and Maintenance of Acute Myeloid Leukaemia

  2018cites this paper
• The potential of precision medicine for childhood acute lymphoblastic leukemia: opportunities and challenges

  2018cites this paper
• BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer

  2018influential citation
• Epigenética en la enfermedad renal: Investigación de las proteínas BET como potenciales dianas terapéuticas

  2018cites this paper
• Structure-guided development of YEATS domain inhibitors by targeting π-π-π stacking

  2018cites this paper
• Prolyl isomerase PIN1 regulates the stability, transcriptional activity and oncogenic potential of BRD4

  2017cites this paper
• Epigenetic assays for chemical biology and drug discovery

  2017cites this paper
• Bromodomain Histone Readers and Cancer.

  2017cites this paper
• Functions of bromodomain-containing proteins and their roles in homeostasis and cancer

  2017cites this paper
• Order Matters: The Order of Somatic Mutations Influences Cancer Evolution.

  2017cites this paper
• Investigating the role of epigenetics in the regulation of inflammatory skin disease

  2016influential citation
• Epigenomic regulation of oncogenesis by chromatin remodeling

  2016cites this paper
• Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.

  2016cites this paper
• BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer

  2016cites this paper
• Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

  2016cites this paper
• Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.

  2016cites this paper
• Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer

  2015cites this paper
• Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.

  2015cites this paper
• Concomitant BET and MAPK blockade for effective treatment of ovarian cancer

  2015cites this paper